Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00177931 · ClinicalTrials.gov registry record
Cefepime Pharmacokinetics in Liver Transplant Recipients in an Intensive Care Unit
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 25
- Enrollment target
NCT00177931: Completed study, sponsored by University of Pittsburgh.
NCT00177931 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00177931 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
The purposes of this study are to: I. Characterize the plasma concentration-time profile of cefepime in liver transplant patients to determine the pharmacokinetic parameters in this patient population. II. Perform stochastic modeling using the population pharmacokinetic parameters obtained in Specific Aim I to determine the ideal dose and dosing regimen of cefepime required to attain predetermined therapeutic targets in liver transplant patients.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2005-03 |
| Est. Completion | 2009-12 |
What the finished NCT00177931 record still lists
NCT00177931 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00177931 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00177931 about?
NCT00177931 is a clinical study titled "Cefepime Pharmacokinetics in Liver Transplant Recipients in an Intensive Care Unit". The purposes of this study are to: I. Characterize the plasma concentration-time profile of cefepime in liver transplant patients to determine the pharmacokinetic parameters in this patient population. II. Perform stochastic modeling using the population pharmacokinetic parameters obtained in Spec...
What is the current status of trial NCT00177931?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2005-03. Estimated completion is 2009-12.
Who is sponsoring clinical trial NCT00177931?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia